دورية أكاديمية
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
| العنوان: | Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) |
|---|---|
| المؤلفون: | Gordon, Leo, Karmali, Reem, Kaplan, Jason, Popat, Rakesh, Burris, Howard A. III, Ferrari, Silvia, Carpio Segura, Cecilia Carmen, Bosch Albareda, Francesc |
| المساهمون: | Institut Català de la Salut, Gordon LI, Karmali R, Kaplan JB Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. Popat R Department of Haematology, NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK. Burris HA 3rd Drug Development, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA. Ferrari S Dipartimento di Oncologia ed Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy. Carpio C Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Bosch F Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Impact Journals |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Sang - Malalties - Tractament, Cèl·lules B - Tumors - Tractament, Proteïnes quinases - Inhibidors - Ús terapèutic, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors, Other subheadings::Other subheadings::/therapeutic use, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::Other subheadings::/drug therapy, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas, Otros calificadores::Otros calificadores::/uso terapéutico, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas |
| الوصف: | Non-Hodgkin’s lymphoma; SYK inhibitor; Relapsed/refractory ; Linfoma no Hodgkin; Inhibidor de SYK; Recidivante/refractario ; Limfoma no Hodgkin; Inhibidor de SYK; Recaiguda/refractària ; We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). Patients with relapsed/refractory lymphoma for which no standard treatment was available received mivavotinib 60–120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity. A total of 124 patients with lymphoma, including 89 with DLBCL, were enrolled. Overall response rates (ORR) in response-evaluable patients were 45% (43/95) and 38% (26/69), respectively. Median duration of response was 28.1 months overall and not reached in DLBCL responders. In subgroups with DLBCL of germinal center B-cell (GCB) and non-GCB origin, ORR was 28% (11/40) and 58% (7/12), respectively. Median progression free survival was 2.0 and 1.6 months in the lymphoma and DLBCL cohorts, respectively. Grade ≥3 treatment-emergent adverse events occurred in 96% of all lymphoma patients, many of which were limited to asymptomatic laboratory abnormalities; the most common were increased amylase (29%), neutropenia (27%), and hypophosphatemia (26%). These findings support SYK as a potential therapeutic target for the treatment of patients with B-cell lymphomas, including DLBCL. ; This study was funded by Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1949-2553 |
| العلاقة: | Oncotarget;14; https://doi.org/10.18632/oncotarget.28352Test; Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA 3rd, Ferrari S, et al. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 Jan 26;14:57–70.; https://hdl.handle.net/11351/9094Test |
| DOI: | 10.18632/oncotarget.28352 |
| الإتاحة: | https://doi.org/10.18632/oncotarget.28352Test https://hdl.handle.net/11351/9094Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.C4AB8BB6 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 19492553 |
|---|---|
| DOI: | 10.18632/oncotarget.28352 |